Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly) have been central to the treatment of advanced disease, the market is set to witness a substantial change within the next 10 years driven by the 2020 approval of Tecentriq (Roche / Genentech) plus bevacizumab, the FDA approval of Imfinzi plus Imjudo (AstraZeneca) and the anticipated entry of novel emerging immune checkpoint inhibitor-based combinations. The anticipated uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma market, where identified unmet needs remain to offer further opportunities for effective therapy development.
Questions answered
Content highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists.
Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech, AstraZeneca.
Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda, Imfinzi, Imjudo.
Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.
Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and Phase II products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.